<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02442531</url>
  </required_header>
  <id_info>
    <org_study_id>CT-CL01</org_study_id>
    <nct_id>NCT02442531</nct_id>
  </id_info>
  <brief_title>A Study of CriPec® Docetaxel Given to Patients With Solid Tumours</brief_title>
  <acronym>NAPOLY</acronym>
  <official_title>A Phase I Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of CriPec® Docetaxel in Patients With Solid Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cristal Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cristal Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this Phase1 clinical research study is to find the highest safe dose of CriPec®
      docetaxel that can be given in the treatment of patients with solid tumours.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed to explore the safety, tolerability, pharmacokinetics and
      pharmacodynamics of CriPec® docetaxel and to identify the Maximum Tolerated Dose (MTD).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Incidence of grade 3 or 4 adverse events (AEs) as a measure of safety and tolerability.</measure>
    <time_frame>9 months</time_frame>
    <description>Part 1: Incidence of grade 3 or 4 adverse events (AEs) will be determined after escalating doses of CriPec® docetaxel once every three weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Incidence of clinical laboratory abnormalities as a measure of safety and tolerability.</measure>
    <time_frame>9 months</time_frame>
    <description>Part 1: Incidence of laboratory abnormalities will be determined after escalating doses of CriPec® docetaxel once every three weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1: Incidence of electrocardiogram (ECG) abnormalities as a measure of safety and tolerability.</measure>
    <time_frame>9 months</time_frame>
    <description>Part 1: Incidence of electrocardiogram (ECG) abnormalities will be determined after escalating doses of CriPec® docetaxel once every three weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Incidence of grade 3 or 4 adverse events (AEs) at the Maximum Tolerated Dose (MTD) of CriPec® docetaxel as defined in Part 1.</measure>
    <time_frame>9 months</time_frame>
    <description>Part 2: Incidence of grade 3 or 4 adverse events (AEs) at the Maximum Tolerated Dose will be determined after CriPec® docetaxel dosing once every three weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Incidence of clinical laboratory abnormalities at the Maximum Tolerated Dose (MTD) of CriPec® docetaxel as defined in Part 1</measure>
    <time_frame>9 months</time_frame>
    <description>Part 2: Incidence of clinical laboratory abnormalities at the Maximum Tolerated Dose will be determined after CriPec® docetaxel dosing once every three weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Incidence of electrocardiogram (ECG) abnormalities at the Maximum Tolerated Dose (MTD) of CriPec® docetaxel as defined in Part 1</measure>
    <time_frame>9 months</time_frame>
    <description>Part 2: Incidence of electrocardiogram (ECG) abnormalities at the Maximum Tolerated Dose will be determined after CriPec® docetaxel dosing once every three weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and 2: Pharmacokinetic profile of CriPec® docetaxel following IV infusion</measure>
    <time_frame>First two cycles of CriPec® docetaxel (each cycle is 3 weeks)</time_frame>
    <description>Pharmacokinetic parameters such as time to peak concentration (Tmax), peak concentration (Cmax), volume of distribution (Vd), half life (t1/2), total body clearance (CL) and area under the concentration-time curve (AUC) will be determined using plasma concentration data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early signs of anti-tumor efficacy (overall response rate [ORR]) of CriPec® docetaxel</measure>
    <time_frame>18 months in total for part 1 and 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early signs of anti-tumor efficacy (duration of response) of CriPec® docetaxel</measure>
    <time_frame>18 months in total for part 1 and 2</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>CriPec® docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel containing nanoparticle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CriPec® docetaxel</intervention_name>
    <description>-3 weekly IV dose. Dose escalation; start dose 15 mg/m2. Number of cycles: 6 or until progression or unacceptable toxicity develops</description>
    <arm_group_label>CriPec® docetaxel</arm_group_label>
    <other_name>Docetaxel containing nanoparticles</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. At least 18 years old

          2. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1

          3. Estimated life expectancy of at least 12 weeks

          4. Ability and willingness to give written informed consent and to comply with the
             requirements of the study

             For Part 1:

          5. Patients with pathologically confirmed diagnosis of advanced, recurrent and
             progressive solid tumours that are refractory to standard therapy or for whom no
             standard therapy exists and with measurable or evaluable disease according to RECIST
             1.1.

             For Part 2:

          6. Patients with pathologically confirmed diagnosis of advanced, recurrent and
             progressive cancer with measurable disease according to RECIST 1.1 of a histological
             type that are refractory to standard therapy or for whom no standard therapy exists
             and where treatment with a taxane is an appropriate treatment option.

        Exclusion Criteria:

          1. Less than 4 weeks since the last treatment of chemotherapy, biological therapy,
             immunotherapy or systemic radiotherapy (except palliative radiation delivered to &lt;20%
             of bone marrow), and less than 6 weeks for nitrosoureas and mitomycin C prior to Cycle
             1 Day 1.

          2. Current or recent (within 4 weeks prior to Cycle 1 Day 1) treatment with another
             Investigational Product or participation in another investigational interventional
             study.

          3. Symptomatic brain metastases.

          4. Toxicities incurred as a result of previous anticancer therapy (radiation therapy,
             chemotherapy, or surgery) that have not resolved to ≤ grade 2 (as defined by CTCAE
             version 4.03).

          5. Inadequate bone marrow function at screening as evidenced by any of the following:

               -  Absolute Neutrophil Count (ANC) &lt; 1.5 x 109/L.

               -  Platelet count &lt; 100 x 109/L.

               -  Haemoglobin &lt; 6.0 mmol/L (&lt; 9.6 g/dL). The patient should not have received a
                  transfusion or growth factors for these abnormalities in the 7 days prior to
                  Cycle 1 Day 1.

          6. Serum (total) bilirubin &gt; 1.5 x the Upper Limit of Normal (ULN) for the institution if
             no liver metastases (&gt; 2 x ULN in patients with liver metastases).

          7. AST or ALT &gt; 2.5 x ULN if no liver metastases (&gt; 5x ULN in patients with liver
             metastases).

          8. Alkaline phosphatase levels &gt; 2.5 x ULN if no liver metastases (&gt; 5 x ULN in patients
             with liver metastases, or &gt; 10 x ULN in patients with bone metastases).

          9. Increased plasma prothrombin time or International Normalized Ratio (INR), consequence
             of reduced hepatic production of Vitamin K.

         10. Hepatitis B surface antigen or hepatitis C positivity with abnormal liver function
             tests.

         11. Medical history of:

               -  Nonalcoholic steatohepatitis (NASH).

               -  History of human immunodeficiency virus (HIV) antibody positive or use of
                  antiretroviral therapy.

               -  Alcoholic and autoimmune hepatitis.

               -  Ischemic hepatitis, Cardiovascular dysfunction or impaired liver oxygenation,
                  including hypotension or right heart failure.

         12. Serum creatinine &gt; 1.5 x ULN.

         13. Estimated Glomerular Filtration Rate of &lt; 50 mL/min/1.73m2 calculated by Modification
             of Diet in Renal Disease (MDRD) formula or creatinine clearance of &lt; 50 mL/min
             calculated by Cockcroft-Gault.

         14. Stroke within 6 months prior to Cycle 1 Day 1.

         15. Transient Ischemic Attack (TIA) within 6 months prior to Cycle 1 Day 1.

         16. Myocardial infarction within 6 months prior to Cycle 1 Day 1.

         17. Unstable angina.

         18. New York Heart Association (NYHA) Grade II or greater Congestive Heart Failure at
             screening.

         19. Serious cardiac arrhythmia requiring medication.

         20. Patients who are pregnant or breastfeeding.

         21. Absence of effective means of contraception in female patients of childbearing
             potential (defined as &lt;2 years after last menstruation and not surgically sterile) or
             in male patients who are not surgically sterile and who have female partners of
             childbearing potential.

         22. Major surgical procedure (including open biopsy and excluding central line intravenous
             catheter) within 28 days prior to the first study treatment, or anticipation of the
             need for major surgery during the course of the study treatment.

         23. Grade ≥2 motor or sensory neuropathy symptoms (as defined by CTCAE version 4.03).

         24. Known hypersensitivity to any of the Investigational Product's excipients or taxanes.

         25. History of drug or alcohol abuse in the opinion of the investigator within 3 years
             before screening.

         26. Evidence of any other medical conditions (such as psychiatric illness, infectious
             diseases, physical examination or laboratory findings) that may interfere with the
             planned treatment, affect patient compliance or place the patient at high risk for
             treatment-related complications.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rob Hanssen, PhD</last_name>
    <phone>+31 43 3885868</phone>
    <email>rob.hanssen@cristaltherapeutics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cristianne Rijcken, PhD</last_name>
    <phone>+31 43 3885868</phone>
    <email>cristianne.rijcken@cristaltherapeutics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Schoffski, MD, PhD</last_name>
      <email>patrick.schoffski@uzleuven.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VUMC Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Willemien Menke, MD,PhD</last_name>
      <email>c.menke@vumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMC Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J.A. Gietema, Md,PhD</last_name>
      <email>j.a.gietema@umcg.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ferry Eskens, MD,PhD</last_name>
      <email>f.eskens@erasmusmc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2015</study_first_submitted>
  <study_first_submitted_qc>May 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2015</study_first_posted>
  <last_update_submitted>September 14, 2017</last_update_submitted>
  <last_update_submitted_qc>September 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

